Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Dec;90(12):1373–1379. doi: 10.1111/j.1349-7006.1999.tb00722.x

Cisplatin‐resistant HeLa Cells Are Resistant to Apoptosis via p53‐dependent and ‐independent Pathways

Yukihisa Minagawa 1,✉, Junzo Kigawa 1, Hiroaki Itamochi 1, Yasunobu Kanamori 1, Muneaki Shimada 1, Masakuni Takahashi 1, Naoki Terakawa 1
PMCID: PMC5926032  PMID: 10665656

Abstract

Since HeLa cells possess very little functional p53 activity, they could be originally resistant to genotoxic stress‐induced apoptosis. Therefore, it is likely that the drug‐resistant cells derived from HeLa cells are more resistant to apoptosis. The aim of this study was to determine whether cisplatin‐resistant cells derived from HeLa cells have an apoptosis‐resistant phenotype. A cisplatin‐resistant cell subline, HeLa/CDDP cells, showed a 19‐fold resistance to cisplatin compared with the parent cells. The subline showed a collateral sensitivity to paclitaxel. An equitoxic dose (IC50) of cisplatin produced DNA fragmentation in HeLa cells but not in HeLa/CDDP cells. Transfection of wild‐type p53gene enhanced the cytotoxicity of cisplatin and cisplatin‐induced apoptosis in HeLa cells but not in HeLa/CDDP cells, although it caused p53 overexpression in both cell lines. The expression of caspase 1 (interleukin‐1β‐converting enzyme, ICE) mRNA and the overexpression of bax protein were observed only in HeLa cells. Paclitaxel‐induced DNA fragmentation appeared less in HeLa/CDDP cells than in HeLa cells. p53gene transfection did not affect the extent of DNA fragmentation in either cell line, suggesting that paclitaxel may induce p53‐independent apoptosis. These findings suggest that HeLa/CDDP cells may have an acquired phenotype that is resistant to p53‐dependent and ‐independent apoptosis.

Keywords: HeLa cells, Cisplatin, Drug‐resistance, Apoptosis, p53

Full Text

The Full Text of this article is available as a PDF (324.2 KB).

REFERENCES

  • 1. ) Dive , C. and Hickman , J. A.Drug‐target interactions: only the first step in the commitment to a programmed cell death ? Br. J. Cancer , 64 , 192 – 196 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. ) Sen , S. and D'Incalci , M.Apoptosis. Biochemical events and relevance to cancer chemotherapy . FEBS Lett. , 307 , 122 – 127 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Barry , M. A. , Behnke , C. A. and Eastman , A.Activation of programmed cell death (apoptosis) by cisplatin, other anti‐cancer drugs, toxins and hyperthermia . Biochem. Pharmacol. , 40 , 2353 – 2362 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Sorenson , C. M. , Barry , M. A. and Eastman , A.Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin . J. Natl. Cancer Inst. , 82 , 749 – 755 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Lane , D. P.Cancer. p53, guardian of the genome . Nature , 358 , 15 – 16 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Kastan , M. B. , Onyekwere , O. , Sidransky , D. , Vogelstein , B. and Craig , R. W.Participation of p53 protein in the cellular response to DNA damage . Cancer Res. , 51 , 6304 – 6311 ( 1991. ). [PubMed] [Google Scholar]
  • 7. ) Kuerbitz , S. J. , Plunkett , B. S. , Walsh , W. V. and Kastan , M. B.Wild‐type p53 is a cell cycle checkpoint determinant following irradiation . Proc. Natl. Acad. Sci. USA , 89 , 7491 – 7495 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Anthoney , D. A. , McIlwrath , A. J. , Gallagher , W. M. , Edlin , A. R. and Brown , R.Microsatellite instability, apoptosis, and loss of p53 function in drug‐resistant tumor cells . Cancer Res. , 56 , 1374 – 1381 ( 1996. ). [PubMed] [Google Scholar]
  • 9. ) Perego , P. , Giarola , M. , Righetti , S. C. , Supino , R. , Caserini , C. , Delia , D. , Pierotti , M. A. , Miyashita , T. , Reed , J. C. and Zunino , F.Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems . Cancer Res. , 56 , 556 – 562 ( 1996. ). [PubMed] [Google Scholar]
  • 10. ) Gallagher , W. M. , Cairney , M. , Schott , B. , Roninson , I. B. and Brown , R.Identification of p53 genetic suppressor elements which confer resistance to cisplatin . Oncogene , 14 , 185 – 193 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) De Feudis , P. , Debernardis , D. , Beccaglia , P. , Valenti , M. , Graniela Sire , E. , Arzani , D. , Stanzione , S. , Parodi , S. , D'Incalci , M. , Russo , P. and Broggini , M.DDP‐induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status . Br. J. Cancer , 76 , 474 – 479 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Fujiwara , T. , Grimm , E. A. , Mukhopadhyay , T. , Zhang , W. W. , Owen‐Schaub , L. B. and Roth , J. A.Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus‐mediated transfer of the wild‐type p53 gene . Cancer Res. , 54 , 2287 – 2291 ( 1994. ). [PubMed] [Google Scholar]
  • 13. ) Fan , S. , Smith , M. L. , Rivet , D. J. , II , Duba , D. , Zhan , Q. , Kohn , K. W. , Fornace , A. J. , Jr. and O'Connor , P. M.Disruption of p53 function sensitizes breast cancer MCF‐7 cells to cisplatin and pentoxifylline . Cancer Res. , 55 , 1649 – 1654 ( 1995. ). [PubMed] [Google Scholar]
  • 14. ) Hawkins , D. S. , Demers , G. W. and Galloway , D. A.Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents . Cancer Res. , 56 , 892 – 898 ( 1996. ). [PubMed] [Google Scholar]
  • 15. ) O'Connor , P. M. , Jackman , J. , Bae , I. , Myers , T. G. , Fan , S. , Mutoh , M. , Scudiero , D. A. , Monks , A. , Sausville , E. A. , Weinstein , J. N. , Friend , S. , Fornace , A. J. , Jr. and Kohn , K. W.Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth‐inhibitory potency of 123 anticancer agents . Cancer Res. , 57 , 4285 – 4300 ( 1997. ). [PubMed] [Google Scholar]
  • 16. ) Burger , H. , Nooter , K. , Boersma , A. W. , Kortland , C. J. and Stoter , G.Lack of correlation between cisplatin‐induced apoptosis, p53 status and expression of Bcl‐2 family proteins in testicular germ cell tumor cell lines . Int. J. Cancer , 73 , 592 – 599 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Kanamori , Y. , Kigawa , J. , Minagawa , Y. , Irie , T. , Oishi , T. , Shimada , M. , Takahashi , M. , Nakamura , T. , Sato , K. and Terakawa , N.A newly developed adenovirus‐mediated transfer of a wild‐type p53 gene increases sensitivity to cis‐diamminedichloroplatinum (II) in p53‐deleted ovarian cancer cells . Eur. J. Cancer , 34 , 1802 – 1806 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Matlashewski , G. , Banks , L. , Pim , D. and Crawford , L.Analysis of human p53 proteins and mRNA levels in normal and transformed cells . Eur. J. Biochem. , 154 , 665 – 672 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Scheffner , M. , Werness , B. A. , Huibregtse , J. M. , Levine , A. J. and Howley , P. M.The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 . Cell , 63 , 1129 – 1136 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Schiff , P. B. and Horwitz , S. B.Taxol stabilizes microtubules in mouse fibroblast cells . Proc. Natl. Acad. Sci. USA , 77 , 1561 – 1565 ( 1980. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Kelland , L. R. and Abel , G.Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin‐sensitive and ‐resistant human ovarian carcinoma cell lines . Cancer Chemother. Pharmacol. , 30 , 444 – 450 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Wu , G. S. and El‐Diery , W. S.p53 and chemosensitivity . Nat. Med. , 2 , 255 – 256 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Debernardis , D. , Sire , E. G. , de Feudis , P. , Vikhanskaya , F. , Valenti , M. , Russo , P. , Parodi , S. , D'Incalci , M. and Broggini , M.p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel . Cancer Res. , 57 , 870 – 874 ( 1997. ). [PubMed] [Google Scholar]
  • 24. ) Graniela Sire , E. A. , Vikhanskaya , F. and Broggini , M.Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild‐type, mutated or no p53 . Ann. Oncol. , 6 , 589 – 593 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Wahl , A. F. , Donaldson , K. L. , Fairchild , C. , Lee , F. Y. , Foster , S. A. , Demers , G. W. and Galloway , D. A.Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis . Nat. Med. , 2 , 72 – 79 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Vikhanskaya , F. , Vignati , S. , Beccaglia , P. , Ottoboni , C. , Russo , P. , D'Incalci , M. and Broggini , M.Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis . Exp. Cell Res. , 241 , 96 – 101 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Woods , C. M. , Zhu , J. , McQueney , P. A. , Bollag , D. and Lazarides , E.Taxol‐induced mitotic block triggers rapid onset of a p53‐independent apoptotic pathway . Mol. Med. , 1 , 506 – 526 ( 1995. ). [PMC free article] [PubMed] [Google Scholar]
  • 28. ) Banerjee , S. , Fallis , A. G. and Brown , D. L.Differential effects of taxol on two human cancer cell lines . Oncol. Res. , 9 , 237 – 248 ( 1997. ). [PubMed] [Google Scholar]
  • 29. ) Torres , K. and Horwitz , S. B.Mechanisms of Taxol‐induced cell death are concentration dependent . Cancer Res. , 58 , 3620 – 3626 ( 1998. ). [PubMed] [Google Scholar]
  • 30. ) Minagawa , Y. , Kigawa , J. , Ishihara , H. , Itamochi , H. and Terakawa , N.Synergistic enhancement of cisplatin cytotoxicity by SN‐38, an active metabolite of CPT‐11, for cisplatin‐resistant HeLa cells . Jpn. J. Cancer Res. , 85 , 966 – 971 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Miller , S. A. , Dykes , D. D. and Polesky , H. F.A simple salting out procedure for extracting DNA from human nucleated cells . Nucleic Acids Res. , 16 , 1215 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. ) Wei , Q. , Xu , X. , Cheng , L. , Legerski , R. J. and Ali‐Osman , F.Simultaneous amplification of four DNA repair genes and β‐actin in human lymphocytes by multiplex reverse transcriptase‐PCR . Cancer Res. , 55 , 5025 – 5029 ( 1995. ). [PubMed] [Google Scholar]
  • 34. ) Fajac , A. , Da Silva , J. , Ahomadegbe , J. C. , Rateau , J. G. , Bernaudin , J. F. , Riou , G. and Bernard , J.Cisplatin‐induced apoptosis and p53 gene status in a cisplatin resistant human ovarian carcinoma cell line . Int. J. Cancer , 68 , 67 – 74 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Segal‐Bendirdjian , E. and Jacquemin‐Sablon , A.Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process . Exp. Cell Res. , 218 , 201 – 212 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Canitrot , Y. , Frit , P. and Salles , B.Deficient apoptotic process in cisplatin‐resistant L1210 cells cannot account for the cellular response to various drug treatments . Biochem. Bio-phys. Res. Commun. , 234 , 573 – 577 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Eichholtz‐Wirth , H. , Stoetzer , O. and Marx , K.Reduced expression of the ICE‐related protease CPP32 is associated with radiation‐induced cisplatin resistance in HeLa cells . Br. J. Cancer , 76 , 1322 – 1327 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. ) Song , K. , Li , Z. , Seth , P. , Cowan , K. H. and Sinha , B. K.Sensitization of cis‐platinum by a recombinant adenovirus vector expressing wild‐type p53 gene in human ovarian carcinomas . Oncol. Res. , 9 , 603 – 609 ( 1997. ). [PubMed] [Google Scholar]
  • 39. ) Perego , P. , Romanelli , S. , Carenini , N. , Magnani , I. , Leone , R. , Bonetti , A. , Paolicchi , A. and Zunino , F.Ovarian cancer cisplatin‐resistant cell lines: multiple changes including collateral sensitivity to Taxol . Ann. Oncol. , 9 , 423 – 430 ( 1998. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES